RMOC work programme

Title Submitted Action Committee Committee meeting Further details Expected guidance
Biosimilar to biosimilar switching 28/12/2018 RMOC work programme topic South
Biosimilar insulin guidance 28/12/2018 RMOC work programme topic South
Melatonin for treatment of insomnia in children with neurodevelopmental disorders and neurogenetic diseases: new medicines review 28/12/2018 RMOC work programme topic North
The product was identified through SPS horizon scanning mechanisms and has been agreed for review through the RMOC system. It has recently been approved by EU licensing authorities. See www.sps.nhs.uk/medicines/melatonin/ for more details.
Hydrocortisone granules in capsules for opening (Alkindi) 28/12/2018 RMOC work programme topic London
Levodopa (inhaled) – adjunctive to oral levodopa for “off episodes” in the management of Parkinson’s disease: new medicines review 28/12/2018 RMOC work programme topic North
The product was identified through SPS horizon scanning mechanisms and has been agreed for review through the RMOC system. It is currently undergoing review by the EU licensing authorities. See www.sps.nhs.uk/medicines/levodopa/ .
for more details
rivaroxaban 2.5mg for PAD/CAD 20/12/2018 RMOC work programme topic North
Doxylamine/pyridoxine (Xonvea) oral for treatment of nausea and vomiting of pregnancy: new medicines review 18/12/2018 RMOC work programme topic North
This product is a fixed-dose combination modified-release tablet containing a histamine H1 receptor antagonist (doxylamine 10mg) and vitamin B6 (pyridoxine 10mg). Its anticipated use is for nausea and vomiting in pregnancy (NVP) in women who do not respond to conservative management. The product was identified through SPS horizon scanning mechanisms and has subsequently been identified as requiring review through the RMOCs.
Sequential use of biologics 17/09/2018 RMOC work programme topic South

More information coming soon

Sodium docusate 10/09/2018 RMOC work programme topic North

More information coming soon

RMOC determination of shared care suitability for new and existing medicines 21/08/2018 RMOC work programme topic North

More information coming soon

National revision of standardised & quality assured shared care templates through RMOC shared care programme of work 21/08/2018 RMOC work programme topic North

More information coming soon

GLP1 choice in those with CVD 15/08/2018 RMOC work programme topic Midlands and East 05/12/2018

Update published - January 2019


A position statement is expected on this topic. The committee noted that clinical trials assessing the impact of several GLP-1 mimetics on cardiovascular outcome have been published in recent years and there is some evidence from clinical trials of potential differences between agents within this class of medicines. Whilst the RMOC is mindful of current NICE guidance and note that NICE will update their guidance in due course there is currently a paucity of robust cost-effectiveness data and a lack of a suitable cost effectiveness model.

National shared care guidelines for immunosupressants from Tertiary Referral Centres 02/08/2018 RMOC work programme topic North

More information coming soon

Proposal to establish and oversee a national ‘do once’ system for organisational medicines governance 04/07/2018 RMOC work programme topic South

Update published - November 2018


The RMOC system is to endorse and give oversight to a national "do once" system for patient group directions.

PIL explaining Prescribing responsibilities between primary & secondary/tertiary care 22/06/2018 RMOC work programme topic North

More information coming soon

Multi Compartment Compliance Aids 14/06/2018 RMOC work programme topic London

Update published - December 2018


A project developing a 'gold standard' approach to multicompartment compliance aids is planned. A scoping document is being prepared.

Primary care monitoring of drugs that fall under specialised comissioning 07/06/2018 RMOC work programme topic North

More information coming soon

Drug decision making for tertiary and super specialist centres 29/05/2018 RMOC work programme topic North

More information coming soon

Prior Approval BlueTeq Standardisation 16/05/2018 RMOC work programme topic South

More information coming soon

Patient Information to explain prescribing responsibilities 14/05/2018 RMOC work programme topic North

More information coming soon

Biosimilar switching programmes – ‘nocebo vs. meaningful differences between products’ 14/05/2018 RMOC work programme topic South

More information coming soon

Cost Comparator Tool to Optimise Best Value Biologic 03/05/2018 RMOC work programme topic South

More information coming soon

Stopping medication 23/04/2018 RMOC work programme topic London

Update published - December 2018


Deprescribing guidance will be developed. A scoping document is being prepared.

Prescribing of insulin in frail and elderly who are being managed at home 17/04/2018 RMOC work programme topic Midlands and East

More information coming soon

Learning Disabilities Mortality Review (LeDeR) 10/04/2018 RMOC work programme topic North

More information coming soon

Evidence for the use of heparinised saline for maintaining patency of intravascular catheters 03/04/2018 RMOC work programme topic London 04/07/2018

Update published - December 2018


The RMOC has reviewed the evidence and will issue a recommendation for the efficacy of heparinised saline versus normal saline for maintaining the patency of intravascular central venous catheters.

31/01/2019
Sodium Oxybate 14/03/2018 RMOC work programme topic Midlands and East 05/12/2018

Update published - January 2019


NHS England has a commissioning policy for sodium oxybate for narcolepsy in children however there is no similar policy for adults. The committee was previously asked to consider the continuation of sodium oxybate in adolescent patients on their transition into adulthood who benefitted from its use for narcolepsy with cataplexy. Additional information was discussed at the most recent meeting and the RMOC recognised that variation in prescribing and access to the drug is in part due to variations in the way specialist sleep services are commissioned and provided. Further discussions with NHS England specialised commissioning are warranted before guidance is issued.

Evidence based recommendation for use of Botox 13/03/2018 RMOC work programme topic South 27/09/2018

Update published - November 2018


The RMOC will identify a list of indications botulinum toxin A is used in, and assess the level of evidence underpinning these indications. The intention is to provide evidence-based recommendations on use of botulinum toxin A in off-label indications, to support a consistent approach to treatment.

28/06/2019
Shared care agreements 09/03/2018 RMOC work programme topic South 03/05/2018

Update published - November 2018


RMOC South discussed guidance from NHS England (Responsibility for prescribing between Primary & Secondary/Tertiary Care), focusing on how RMOCs can achieve their expectations as set out in section 6 of this guidance. A survey was sent across the South region to identify the types of issues that organisations have with shared care.

Regional availability of rarely used and emergency medicines 25/01/2018 RMOC work programme topic London 01/03/2018

Guidance published - May 2018
Update published - December 2018


London RMOC supports a proposed service specification for pan-regional storage of antidotes. A national antidote storage audit has been conducted and results will be published in 2019. A position statement on rarely used urgent medicines is being produced.

22/05/2018